Phase 1/2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients With FOXG1 Syndrome (FS)

Enrolling by invitation · Phase 1/Phase 2

Conditions studied: FOXG1 Syndrome

In brief

The goal of this clinical trial is to learn if FRF-001 is a safe, tolerable, and efficacious treatment for children and adults with FOXG1 syndrome.

Key facts

Study ID
NCT07293546
Run by
FOXG1 Research Foundation
People needed
12
Starts
2026-07-20
Expected to finish
2029-12-01
Last updated by the study team
2026-07-24

Who can join

Age: 2 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.